New hope for Hard-to-Treat cancers: targeted drug E303 enters human trials
NCT ID NCT07524348
First seen Apr 14, 2026 · Last updated Apr 28, 2026 · Updated 2 times
Summary
This early-stage trial tests a new drug called E303 in people with advanced solid tumors that have not responded to standard treatments. The drug works by targeting a protein called nectin-4 found on many cancer cells. The main goals are to check safety and see if the drug can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGFairfax, Virginia, 22031, United States
Conditions
Explore the condition pages connected to this study.